Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Trial Profile

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2018

At a glance

  • Drugs CA-4948 (Primary)
  • Indications Acute myeloid leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Curis
  • Most Recent Events

    • 15 Aug 2018 Planned number of patients changed from 120 to 80.
    • 02 Aug 2018 According to a Curis media release, the company is extending this Phase I clinical trial to enrol a cohort of patients with acute myeloid leukemia (AML), an update is expected in 2H 2018.
    • 18 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top